Chapter 5. Platinum Drugs

  1. Sotiris Missailidis
  1. Teni Boulikas,
  2. Alexandros Pantos,
  3. Evagelos Bellis,
  4. Petros Christofis

Published Online: 7 NOV 2008

DOI: 10.1002/9780470697047.ch5

Book Title

Anticancer Therapeutics

Anticancer Therapeutics

Additional Information

How to Cite

Boulikas, T., Pantos, A., Bellis, E. and Christofis, P. (2008) Platinum Drugs, in Anticancer Therapeutics (ed S. Missailidis), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470697047.ch5

Editor Information

  1. Department of Chemistry and Analytical Sciences, The Open University, Milton Keynes, UK

Author Information

  1. Regulon Inc. (USA), Afxentiou 7, Alimos, Athens, Greece

Publication History

  1. Published Online: 7 NOV 2008
  2. Published Print: 21 NOV 2008

ISBN Information

Print ISBN: 9780470723036

Online ISBN: 9780470697047

SEARCH

CHAPTER TOOLS

Get PDF (1074K)

Keywords:

  • epithelial malignancy cisplatin treatment;
  • platinum drugs;
  • neutrophil gelatinase-associated lipocalin (NGAL) renal biomarker;
  • lipoplatin formulation and dipalmitoyl phosphatidyl glycerol (DPPG);
  • lipoplatin - primary tumour targeting;
  • oxaliplatin alkaline hydrolysis;
  • new platinum-based anticancer drugs;
  • conjugating DNA-targeting groups to metal moiety

Summary

This chapter contains sections titled:

  • Cisplatin

  • Lipoplatin

  • Carboplatin

  • Oxaliplatin

  • Lipoxal

  • New Platinum Compounds

  • Cisplatin Resistance and Chemotherapy

  • References

Get PDF (1074K)